BRPI0407926A - 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas - Google Patents

4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas

Info

Publication number
BRPI0407926A
BRPI0407926A BRPI0407926-4A BRPI0407926A BRPI0407926A BR PI0407926 A BRPI0407926 A BR PI0407926A BR PI0407926 A BRPI0407926 A BR PI0407926A BR PI0407926 A BRPI0407926 A BR PI0407926A
Authority
BR
Brazil
Prior art keywords
triazole
amino
quinoxalines
substituted
prodrugs
Prior art date
Application number
BRPI0407926-4A
Other languages
English (en)
Inventor
John William Benbow
Margaret Yuhua Chumoyer
Daniel Wei-Shung Kung
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0407926A publication Critical patent/BRPI0407926A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"4-AMINO¢1,2,4!TRIAZOL¢4,3-a!QUINOXALINAS SUBSTITUìDAS". A presente invenção refere-se a 4-amino¢1,2,4!triazol¢4,3-a!quinoxalinas substituídas, da fórmula (I), seus pró-medicamentos, e os sais farmaceuticamente aceitáveis dos compostos e pró-medicamentos, onde R¬ a¬, R¬ b¬, R¬ 1¬ e R¬ 2¬ são como aqui definidos; suas composições; que são inibidores de glicogênio sintetase cinase-3 (GSK-3), e desta forma, são úteis no tratamento de, inter alia, condições, doenças e sintomas tais como diabetes, demência, Doença de Alzheimer, distúrbio bipolar, acidente vascular cerebral, esquizofrenia, depressão, alopecia, câncer, e similares.
BRPI0407926-4A 2003-03-27 2004-03-15 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas BRPI0407926A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45850003P 2003-03-27 2003-03-27
PCT/IB2004/000835 WO2004085439A1 (en) 2003-03-27 2004-03-15 Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines

Publications (1)

Publication Number Publication Date
BRPI0407926A true BRPI0407926A (pt) 2006-02-21

Family

ID=33098270

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407926-4A BRPI0407926A (pt) 2003-03-27 2004-03-15 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas

Country Status (7)

Country Link
US (1) US7202245B2 (pt)
EP (1) EP1613629A1 (pt)
JP (1) JP2006521343A (pt)
BR (1) BRPI0407926A (pt)
CA (1) CA2520251A1 (pt)
MX (1) MXPA05010293A (pt)
WO (1) WO2004085439A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035532A1 (en) * 2003-10-10 2005-04-21 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
AU2005210623A1 (en) * 2004-01-30 2005-08-18 Axonyx, Inc. Methods for treatment of complications of diabetes
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MX2008009475A (es) * 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009004140A (es) * 2006-10-21 2009-07-10 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR20110132559A (ko) 2009-03-05 2011-12-08 아스텔라스세이야쿠 가부시키가이샤 퀴녹살린 화합물
US8481547B2 (en) * 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
EA201390354A1 (ru) 2010-09-07 2013-08-30 Астеллас Фарма Инк. Хиноксалиновое соединение
US9540379B2 (en) * 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
ES2687693T3 (es) * 2011-09-30 2018-10-26 C&C Research Laboratories Nuevos derivados heterocíclicos y sus usos
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
RS63671B1 (sr) * 2018-07-20 2022-11-30 Gruenenthal Gmbh Supstitutisani derivati triazolo hinoksalina
CN116462676A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CA3257212A1 (en) * 2022-08-03 2025-03-19 Abbisko Therapeutics Co., Ltd. Fused three-cycle PRMT5 inhibitor containing nitrogen, its preparation process and its pharmaceutical use
CN119585276A (zh) * 2022-08-09 2025-03-07 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
IL319814A (en) * 2022-09-26 2025-05-01 Shanghai Apeiron Therapeutics Company Ltd A novel inhibitor of protein arginine methyltransferase 5 and its use
WO2025077857A1 (zh) * 2023-10-13 2025-04-17 上海湃隆生物科技有限公司 Prmt5抑制剂在治疗肿瘤或癌症中的用途
TW202540110A (zh) * 2024-02-26 2025-10-16 大陸商上海湃隆生物科技有限公司 化合物鹽的晶型及其製備方法和用途
WO2025180349A1 (zh) * 2024-02-26 2025-09-04 上海湃隆生物科技有限公司 化合物的固体及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US103185A (en) * 1870-05-17 Improvement in combined rake and reel for harvesters
CA2310072A1 (en) * 1997-11-11 1999-05-20 Hiroyuki Ohno Fused pyrazine compounds
AU2002225096B8 (en) * 2000-12-20 2006-07-27 Ipsen Pharma S.A.S. Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US6958334B2 (en) * 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives

Also Published As

Publication number Publication date
WO2004085439A1 (en) 2004-10-07
CA2520251A1 (en) 2004-10-07
EP1613629A1 (en) 2006-01-11
US20040192698A1 (en) 2004-09-30
JP2006521343A (ja) 2006-09-21
US7202245B2 (en) 2007-04-10
MXPA05010293A (es) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0407926A (pt) 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
BRPI0414136A (pt) indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
CA2417652A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
BRPI0415185A (pt) 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
YU14003A (sh) Biciklična heterociklična jedinjenja, lekovi koji sadrže ova jedinjenja, njihova primena i postupak za njihovo dobijanje
WO2006067445A3 (en) Csf-1r kinase inhibitors
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
ATE443063T1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
JO2293B1 (en) Derivatives of 3-indoleil 4-phenyl-1H-birol-5.2 -Dayon as inhibitors of glycogen synthacinase-3b
WO2006028957A8 (en) 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
MXPA03001377A (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
BR0312232A (pt) Inibidores de caspases e seus usos
BR0313634A (pt) Derivados de benzimidazol
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
WO2006116733A3 (en) Protein kinase inhibitors
BRPI0410940A (pt) benzo[b]tiofenos substituìdos com cicloalquilsulfanila como agentes terapêuticos
WO2001027080A3 (de) In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.